Search

Displaying results 1571 - 1580 of 1723 in total
  1. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults.

  2. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    [A199002] Daratumumab was granted FDA approval on 16 November 2015.

  3. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    [L31218] This [cyclosporine] A analog was approved by the FDA on January 22, 2021 following promising results in clinical trials.

  4. Drug

    Metreleptin

    go.drugbank.com/drugs/DB09046
    ApprovedInvestigational

    [L41315] In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized

  5. Drug

    Velmanase alfa

    go.drugbank.com/drugs/DB12374
    ApprovedInvestigational

    [A244509] In February 2023, the FDA also approved velmanase alfa for the same indication.[L45295] Velmanase alfa is currently not approved in Canada.

  6. Drug

    Conjugated estrogens

    go.drugbank.com/drugs/DB00286
    ApprovedInvestigational

    [T484] The currently approved product of conjugated estrogens was developed by Wyeth Ayerst and FDA approved in 2003.[L5608]

  7. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    [A254187] In December 2020, the FDA placed a partial clinical hold and requested the drug developer, Regeneron Pharmaceuticals, to amend clinical protocols to reduce the incidence of CRS.

  8. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    [A258318] The FDA approved the use of vardenafil for the treatment of erectile dysfunction in 2003.

  9. Drug

    Mefloquine

    go.drugbank.com/drugs/DB00358
    Approved

    It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche.

  10. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March 2020 for the same indication.[L12162]